Immune and cell therapy in type 1 diabetes: too little too late?

ISSN： 1471-2598

Source： Expert Opinion on Biological Therapy, Vol.11, Iss.5, 2011-05, pp. : 609-621

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Teplizumab therapy for type 1 diabetes

By Masharani Umesh B Becker Joseph

Expert Opinion on Biological Therapy, Vol. 10, Iss. 3, 2010-03 ,pp. : 459-465

Informa Healthcare

Access to resources Recommend Favorite

DiaPep277 peptide therapy in the context of other immune intervention trials in type 1 diabetes

By Tuccinardi Dario Fioriti Elvira Manfrini Silvia D'Amico Eugenio Pozzilli Paolo

Expert Opinion on Biological Therapy, Vol. 11, Iss. 9, 2011-09 ,pp. : 1233-1240

Informa Healthcare

Access to resources Recommend Favorite

Roles of cytokines in the pathogenesis and therapy of type 1 diabetes

By Rabinovitch Alex Suarez-Pinzon Wilma

Cell Biochemistry and Biophysics, Vol. 48, Iss. 2-3, 2007-07 ,pp. : 159-163

Humana Press, Inc

Access to resources Recommend Favorite

Cell therapies for type 1 diabetes mellitus

By Shamblott Michael J Clark Gregory O

Expert Opinion on Biological Therapy, Vol. 4, Iss. 3, 2004-03 ,pp. : 269-277

Informa Healthcare

Access to resources Recommend Favorite

Genomics of Type 1 Diabetes Mellitus and Its Late Complications

By Nosikov V. V.

Molecular Biology, Vol. 38, Iss. 1, 2004-01 ,pp. : 128-139

MAIK Nauka/Interperiodica

Access to resources Recommend Favorite